Clinical trial NCT01092533 - References

Uveitis, Intermediate — Myfortic for the Treatment of Non-infectious Intermediate Uveitis

Citation(s)

•   Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS
  Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003 May;110(5):1061-5.
•   Behrend M
  Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 2001;24(9):645-63. Review.
•   Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M; ERL B302 Study Group
  . Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004 Feb;4(2):237-43.
•   Chanaud NP 3rd, Vistica BP, Eugui E, Nussenblatt RB, Allison AC, Gery I
  Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res. 1995 Oct;61(4):429-34.
•   Hachinski VC, Wilson JX, Smith KE, Cechetto DF
  Effect of age on autonomic and cardiac responses in a rat stroke model. Arch Neurol. 1992 Jul;49(7):690-6.
•   Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group
  . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. Review.
•   Lau CH, Comer M, Lightman S
  Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol. 2003 Dec;31(6):487-91.
•   Mód A, Tamáska J, Adám E, Gidáll J, Poros A, Király A, Natonek K, Pálóczi K, Hollán Z
  [Importance of the detection of minimal residual disease in the management of acute leukemia]. Orv Hetil. 1991 Jun 16;132(24):1291-6, 1299. Review. Hungarian.
•   Pleyer U, Ruokonen P, Schmidt N, Feist E, Höhne M, Stanojlovic S
  [Mycophenol acid in ocular automimmune disorders--can we optimise this therapy?]. Klin Monbl Augenheilkd. 2008 Jan;225(1):66-9. doi: 10.1055/s-2008-1027134. German.
•   Siepmann K, Huber M, Stübiger N, Deuter C, Zierhut M
  Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol. 2006 Jul;244(7):788-94. Epub 2005 Sep 15.
•   Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP
  Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005 Aug;112(8):1472-7.
•   Whitcup SM
  Intermediate uveitis. In: Nussenblatt RB, Whitcup SM (eds.). Uveitis. Fundamentals and clinical practice. Elsevier publishers 2004: 291-300
•   Zierhut M, Stübiger N, Aboalchamat W, Landenberger H, Bialasiewicz AA, Engelmann K
  [Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis]. Ophthalmologe. 2001 Jul;98(7):647-51. German.

Myfortic (Enteric-coated Mycophenolate Sodium) for the Treatment of Non-infectious Intermediate Uveitis - a Prospective, Controlled, Randomized Multicenter Trial

Details for clinical trial NCT01092533